Why Jounce Therapeutics Shares Are Trading Higher By 23%? Here Are Other Stocks Moving In Monday's Mid-Day Session

Gainers

• Crown ElectroKinetics Corp. (NASDAQ:CRKN) shares jumped 59.6% to $0.2513. Crown Electrokinetics said it has entered into an agreement with a leading infrastructure solutions provider.
• First Citizens BancShares, Inc. (NASDAQ:FCNCA) shares surged 42.5% to $829.82 after First-Citizens Bank & Trust Company entered an agreement to purchase all deposits and loans of Silicon Valley Bank.
• Alpine Acquisition Corporation (NASDAQ:REVE) surged 32% to $14.17.
• Coeptis Therapeutics Holdings, Inc. (NASDAQ:COEP) shares jumped 30% to $1.93 after gaining 8% on Friday.
• Jounce Therapeutics, Inc. (NASDAQ:JNCE) gained 23% to $1.86. Jounce Therapeutics entered into agreement to be acquired by Concentra Biosciences for $1.85 in cash per share plus contingent value rights.
• Silvergate Capital Corporation (NYSE:SI) gained 21.5% to $2.09. Silvergate Capital shares jumped 52% on Friday as traders circulated a rumor that a crypto exchange is trying to buy the company's trade processing technologies.
• Cimpress plc (NASDAQ:CMPR) jumped 21.4% to $37.91. Truist Securities maintained Cimpress with a Buy and raised the price target from $45 to $50.
• Gorilla Technology Group Inc. (NASDAQ:GRRR) surged 20.5% to $9.81.
• Pyxis Oncology, Inc. (NASDAQ:PYXS) gained 20.4% to $2.66. Pyxis Oncology recently reported loss of $3.65 per share in FY22.
• Cyclerion Therapeutics, Inc. (NASDAQ:CYCN) rose 20.2% to $0.5248. Cyclerion Therapeutics received US FDA orphan drug designation for Zagociguat for treatment of mitochondrial diseases.
• FG Financial Group, Inc. (NASDAQ:FGF) rose 20% to $2.58 after posting a narrower quarterly loss.
• Delcath Systems, Inc. (NASDAQ:DCTH) gained 19.8% to $5.80 after reporting Q4 results. The FDA has accepted the company’s New Drug Application resubmission for HEPZATO Kit (melphalan hydrochloride for injection/hepatic delivery system) seeking approval for unresectable hepatic-dominant metastatic ocular melanoma.
• Berkshire Grey, Inc. (NASDAQ:BGRY) jumped 19.4% to $1.3606 as the company entered into definitive merger agreement with SoftBank Group for a go-private transaction.
• Loop Industries, Inc. (NASDAQ:LOOP) gained 17.9% to $2.24.
• First Republic Bank (NYSE:FRC) shares climbed 15.9% to $14.32 in sympathy with Silicon Valley Bank after First Citizens BancShares announced it will purchase all loans and certain other assets of SVB.
• Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) gained 12.9% to $1.75. The FDA will hold an Advisory Committee meeting to discuss the company’s application for NurOwn for amyotrophic lateral sclerosis.
• Blackbaud, Inc. (NASDAQ:BLKB) gained 12.9% to $65.32 over reports of a possible takeover offer. However, after reviewing the offer, Blackbaud's board rejected the non-binding proposal from Clearlake Capital Group, L.P., to acquire all of the company's outstanding shares for $71.00 per share in cash.
• Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) shares rose 11.7% to $6.18. Iovance Biotherapeutics completed Biologics License Application submission for Lifileucel in advanced melanoma.
• Roku, Inc. (NASDAQ:ROKU) gained 8.6% to $65.17. Susquehanna upgraded Roku from Neutral to Positive and announced a $75 price target.
• Harrow Health, Inc. (NASDAQ:HROW) climbed 7.8% to $19.87. The company recently posted upbeat quarterly earnings.
• CytomX Therapeutics, Inc. (NASDAQ:CTMX) rose 7.1% to $1.82. CytomX Therapeutics is expected to report full year 2022 financial results on Monday, March 27, 2023, after the closing bell.
• Novartis AG (NYSE:NVS) surged 7% to $89.42 after the company announced positive results from a trial of its breast cancer treatment.
• KeyCorp (NYSE:KEY) climbed 5% to $12.44. Citigroup upgraded KeyCorp from Neutral to Buy and announced a $20 price target.

Losers

• Unity Biotechnology, Inc. (NASDAQ:UBX) shares dipped 46.3% to $2.23 after the company said its phase 2 ENVISION study did not meet its non-inferiority threshold due to strength in the control group.
• Near Intelligence, Inc. (NASDAQ:NIR) shares tumbled 25.5% to $9.07.
• Pharming Group N.V. (NASDAQ:PHAR) fell 18.9% to $12.31. The FDA approved Pharming Group’s Joenja (leniolisib) for activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS) in adult and pediatric patients 12 years of age and older.
• Virios Therapeutics, Inc. (NASDAQ:VIRI) fell 12.4% to $0.3899 after jumping around 44% on Friday.
• Bird Global, Inc. (NASDAQ:BRDS) fell 11.2% to $0.1331 after gaining over 5% on Friday.
• YS Biopharma Co., Ltd. (NASDAQ:YS) dropped 10.6% to $4.2819 after the company reported interim Phase 2 safety and immunogenicity data for its PIKA recombinant Covid-19 vaccine.
• ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) dipped 10.5% to $6.79. ARS Pharmaceuticals recently posted a FY22 loss of $0.87 per share.
• Ribbon Communications Inc. (NASDAQ:RBBN) dropped 10% to $3.3750.
• Boxed, Inc. (NYSE:BOXD) shares fell 9.8% to $0.2194 after dropping over 29% on Friday.
• Vigil Neuroscience, Inc. (NASDAQ:VIGL) dropped 9.8% to $11.01. Morgan Stanley maintained Vigil Neuroscience with an Equal-Weight and raised the price target from $12 to $13.
• Frontier Communications Parent, Inc. (NASDAQ:FYBR) fell 9.1% to $21.42. Frontier partnered with YouTube TV to deliver internet & tv experience. Morgan Stanley downgraded Frontier Communications from Equal-Weight to Underweight and lowered the price target from $23 to $19.
• Loop Media, Inc. (NYSE:LPTV) fell 8.3% to $5.03.
• PepGen Inc. (NASDAQ:PEPG) dropped 8.1% to $14.00. PopGen recently reported Q4 and full year 2022 financial results.
• Motorsport Games Inc. (NASDAQ:MSGM) fell 7% to $6.22 after the company posted downbeat results for its fourth quarter on Friday.
• Pear Therapeutics, Inc. (NASDAQ:PEAR) shares fell 6.7% to $0.2703 after jumping over 15% on Friday.
• Coinbase Global, Inc. (NASDAQ:COIN) dropped 6.6% to $63.32 after Barclays maintained an Equal-Weight rating on the stock and lowered its price target from $86 to $70.

Now Read This: Wall Street's Most Accurate Analysts Say Hold These 3 Health Care Stocks With Over 3% Dividend Yields